Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14570MR)

This product GTTS-WQ14570MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14570MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ114MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ7122MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ11593MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ10514MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ9265MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6615MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ975MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ13762MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW